Drug Profile

TATX 21

Alternative Names: TATX-21

Latest Information Update: 11 Apr 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Talem Therapeutics
Class Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Monoclonal antibodies
Mechanism of Action ACVRL1 protein agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

10 Apr 2023 TATX 21 is available for licensing as of 10 Apr 2023 https://talemtherapeutics.com/ (Talem Therapeutics pipeline, April 2023).
10 Apr 2023 Discontinued - Preclinical for Atherosclerosis in USA (Parenteral) prior to April 2023 (Talem Therapeutics pipeline, April 2023).
10 Apr 2023 Discontinued - Preclinical for Cardiovascular disorders in USA (Parenteral) prior to April 2023 (Talem Therapeutics pipeline, April 2023).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com